Issue 28, February 2011
7. Diabetes Medicine Updates
Sanofi-aventis announces GetGoal-X Phase III study of lixisenatide against type 2 diabetes
   French pharmaceutical giant Sanofi-Aventis announced that the GetGoal-X Phase III study of lixisenatide, a once-daily GLP-1 receptor agonist licensed from Denmark’s Zealand Pharma, achieved its primary endpoint of non-inferiority in HbA1c reduction from baseline, compared with exenatide twice-daily.  In addition, the initial results showed that significantly fewer people with type-2 diabetes treated with lixisenatide once-daily, reported hypoglycemic events versus patients treated with exenatide.
Previous | Home | Next